Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is a promising investment due to their strong financial performance, conservative approach, and potential for growth through new products and partnerships. While their stock is currently undervalued, the launch of TruVu and promising pipeline for Alzheimer's diagnostics could drive significant growth and recapture market share. However, there are potential risks to consider with any investment, such as changing reimbursement and competition in the radiopharmaceutical industry.

Bears say

Lantheus Holdings is facing headwinds in its Radiopharmaceutical Oncology segment, with a decline in net ASP and volume despite the growing PSMA PET market. The delayed CEO successor announcement could signal potential disruptions in the company's long-term growth plans, and while there are some promising opportunities in the pipeline, there is uncertainty around their potential contribution to revenue. In addition, the change in price target to $115 based on a 20x multiple of the 2027 earnings per share highlights the company's current struggles to maintain its competitive edge.

Lantheus Holdings (LNTH) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 7 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Jul 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.